J Pharm Pharmacogn Res 3(suppl. 1): S132, 2015
Proceedings of the 4th International Symposium on Pharmacology of Natural Products FAPRONATURA 2015 September 21st-25th, 2015; Cuban Society of Pharmacology. Topes de Collantes, Sancti Spiritus, Cuba.
PTS-40: DERMAL AND OCULAR IRRITATION STUDIES OF TWO CREAMS INTENDED FOR ITS USE FOR PSORIASIS
Rivero Y1, González Y1, Mancebo A1, Scull I2, Arteaga ME1, González C1, Bada AM1.
Introduction: The introduction of novel materials into clinical practices requires safety evaluations as well as an understanding of the impact of the products on human health. Sebomori and Psomori are two creams intended for use as a lubricant for the skin affected by psoriasis. The active ingredients of Sebomori are extracts of plants Jacobinia mohintle and Morinda citrifolia, while the active ingredients of Psomori are extracts of plant Morinda citrifolia and seed oil of Azaridachta indica (Nim). Skin and eyes have the highest risk of exposure to Psomori and Sebomori, because deposition to the superficial organs has the potential to be a major route of exposure during the manufacturing, use, and disposal of these products. Material and Methods: This study was performed to examine the potential irritating of Psomori and Sebomori on the skin and eyes. The dermal and eye irritation study was performed using rabbits according to the Organisation for Economic Co-operation and Development (OECD) Guidelines 404 and 405, respectively. The substances in the test were the maximum allowable for administration according to regulations, using the commercial formulation. Results: No dermal responses, including erythema/eschar or edema, were found in rabbits treated with tested subtances. No rabbits exhibited corneal opacity, abnormality of the iris, or chemosis eye at any time point after the application of Sebomori and Psomori. Conclusions: Both products were classified as Non Irritant.
Citation Format: Rivero Y, González Y, Mancebo A, Scull I, Arteaga ME, González C, Bada AM (2015) Dermal and ocular irritation studies of two creams intended for its use for psoriasis. [Abstract]. In: Proceedings of the FAPRONATURA 2015; 2015 Sep 21-25; Topes de Collantes, Sancti Spiritus: CSF. J Pharm Pharmacogn Res 3(Suppl. 1): S132. Abstract nr PTS-40.